13F HOLDINGS REPORT
TAKEDA PHARMACEUTICAL CO LTD
Quarter ended Q3 2025 · Filed November 13, 2025 · Accession 0001395064-25-000157
Total Value
$16.4M
Positions
9
Other Managers
1
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Ovid Therapeutics, Inc. | OVID | 5,750,000 | $7.5M | 45.67% |
| 2 | Equillium, Inc. | EQ | 1,824,977 | $2.6M | 15.94% |
| 3 | Ovid Therapeutics, Inc. | OVID | 1,781,996 | $2.3M | 14.15% |
| 4 | Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics) | XLO | 1,475,121 | $1.2M | 7.59% |
| 5 | Shattuck Labs, Inc. | STTK | 515,619 | $1.2M | 7.53% |
| 6 | Lyell Immunopharma, Inc. | LYEL | 54,887 | $891,365 | 5.45% |
| 7 | American Well Corporation | AMWL | 77,733 | $478,061 | 2.92% |
| 8 | Rani Therapeutics Holdings, Inc. | RANI | 203,190 | $101,554 | 0.62% |
| 9 | Standard Biotools, Inc. | LAB | 16,515 | $21,470 | 0.13% |